Longevity & AgingVyvgart Fails to Beat Placebo in Late-Stage Sjögren’s Disease Trial
Vyvgart failed to outperform placebo in a Phase 3 trial involving patients with Sjögren’s disease, a chronic autoimmune disorder, according to Argenx. The result marks an unusual setback for a company that has reported successes across other autoimmune conditions. For patients, the key lesson is that a drug’s effectiveness in one disease does not guarantee benefits in another. The available STAT News excerpt provides no participant numbers, numerical results, treatment duration, or safety findings, so it cannot explain how large the differences were or why the trial failed. Argenx’s stock fell 13% Thursday morning, but market reactions do not establish clinical significance. Patients should discuss treatment options with their specialist rather than change medications based on this report. Detailed trial results are needed to assess the findings more fully.
